title: Capecitabine and vinorelbine as first-line treatment in elderly patients (> or =65 years) with metastatic breast cancer. A phase II trial (SAKK 25/99).
abstract: BACKGROUND
  We evaluated previously established regimens of capecitabine plus vinorelbine in older patients with advanced breast cancer stratified for presence versus absence of bone metastases.
  
  
  METHODS
  Patients > or =65 years who had received no prior chemotherapy for advanced breast cancer received up to six 21-day cycles of vinorelbine 20 mg/m(2) i.v. on days 1 + 8 with oral capecitabine on days 1-14 (1,000 vs. 1,250 mg/m(2) daily in patients with vs. without bone involvement).
  
  
  RESULTS
  Median age was 72 years in patients with bone metastases (n = 47) and 75 years in patients without bone metastases (n = 23). Response rates were 43% (95% confidence interval, CI, 28.3-58.8) and 57% (95% CI = 34.5-76.8), respectively. Median time to progression was 4.3 (95% CI = 3.5-6.0 months) and 7.0 months (CI = 4.1-8.3), respectively. Neutropenia was the most common toxicity, with grade 3/4 occurring in 43 and 39%, respectively. Pulmonary embolism was seen in 5 and grade 3 thrombosis in 3 patients. Other toxicities were mild to moderate.
  
  
  CONCLUSIONS
  These regimens of capecitabine and vinorelbine are active and well tolerated in patients with advanced breast cancer > or =65 years. Response rates were comparable to published results. The lower capecitabine doses appeared appropriate given the advanced age, bone involvement and prior radiotherapy.
authors.affiliation: Department of Internal Medicine, Division of Oncology-Hematology, Kantonsspital St. Gallen, St. Gallen, Switzerland. dagmar.hess@kssg.ch
authors.forename: D
authors.initials: D
authors.lastname: Hess
authors.forename: D
authors.initials: D
authors.lastname: Koberle
authors.forename: B
authors.initials: B
authors.lastname: Thurlimann
authors.forename: O
authors.initials: O
authors.lastname: Pagani
authors.forename: A
authors.initials: A
authors.lastname: Schonenberger
authors.forename: S
authors.initials: S
authors.lastname: Mattmann
authors.forename: C
authors.initials: C
authors.lastname: Rochlitz
authors.forename: D
authors.initials: D
authors.lastname: Rauch
authors.forename: J C
authors.initials: JC
authors.lastname: Schuller
authors.forename: P
authors.initials: P
authors.lastname: Ballabeni
authors.forename: K
authors.initials: K
authors.lastname: Ribi
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001859:Bone Neoplasms / Q000188:drug therapy* / Q000556:secondary; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000473:pathology; D000069287:Capecitabine; D015331:Cohort Studies; D003841:Deoxycytidine / Q000008:administration & dosage / Q000031:analogs & derivatives; D018450:Disease Progression; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage / Q000031:analogs & derivatives; D006801:Humans; D008113:Liver Neoplasms / Q000188:drug therapy / Q000556:secondary; D008175:Lung Neoplasms / Q000188:drug therapy / Q000556:secondary; D020714:Maximum Tolerated Dose; D012878:Skin Neoplasms / Q000188:drug therapy / Q000556:secondary; D016896:Treatment Outcome; D014747:Vinblastine / Q000008:administration & dosage / Q000031:analogs & derivatives; D000077235:Vinorelbine
chemical_list: D003841:Deoxycytidine; D014747:Vinblastine; D000069287:Capecitabine; D000077235:Vinorelbine; D005472:Fluorouracil